CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats

Sleep and Breathing - Tập 24 Số 4 - Trang 1441-1449 - 2020
Zhanjun Dou1, Xiao-Ling Gao2, Yanli Jia3, Jie Chen2, Jiaojiao Yang1, Yan Chen2, Shu‐Jie Wu4, Tao Liu1, Meiting Wang1, Chong Yang1, Na Zhang1, Bei Wang2
1Department of the Second Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China
2Department of Respiratory and Critical Care Medicine, The Second Hospital of Shanxi Medical University, No. 382, Wuyi Road, Taiyuan, 030001, Shanxi, People's Republic of China
3Department of Respiratory, Linfen Centrol Hospital, Linfen, Shanxi, People's Republic of China
4Medical Records Statistics Office, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China

Tóm tắt

Abstract Objective The endocannabinoid system (ECS) regulates bone turn-over and remodeling. Chronic intermittent hypoxia (CIH) occurring during obstructive sleep apnea (OSA) may lead to disorders of the ECS and bone metabolism abnormalities. This study aimed to investigate whether or not the cannabinoid receptor 1 (CB1R) antagonist rimonabant (Ri) alleviates bone metabolism abnormalities and bone destruction induced by chronic intermittent hypoxia (CIH). Methods Healthy male Sprague Dawley (SD) rats (n=48) were randomly divided into 6 groups of 8 rats: 2 normal control (NC) groups, 2 intermittent hypoxia (IH) groups, and 2 IH + Ri groups. Rats in NC groups breathed room air for 4 weeks (4w NC group) and 6 weeks (6w NC group). Rats in IH groups experienced IH environment for 4 weeks (4w IH group) and 6 weeks (6w IH group). In addition to the same IH exposure, rats in IH + Ri group were given daily intraperitoneal injection of Ri at the dosage of 1.5 mg/kg/d for 4 weeks (4w IH + Ri group) and 6 weeks (6w IH + Ri group). Levels of serum tartrate-resistant acid phosphatase (TRAP, a marker of bone resorption) were determined by ELISA. Hematoxylin and eosin (HE) staining was performed on bone sections to observe the changes in bone microstructure. Expression of CB1R in bone tissue was determined by immunohistochemistry. Results TRAP levels were higher in the 4w IH and 6w IH groups than in the 4w NC and 6w NC groups; TRAP levels were lower in the 4w IH + Ri and 6w IH + Ri groups than in the 4w IH and 6w IH groups. HE staining showed that the morphology of bone cells in the NC group was normal, but the 4w IH group had mild edema of bone cells, reduction in trabecular bone, and destruction of bone microstructure. Changes were more severe in the 6w IH group than 4w IH. The 4w IH + Ri group was slightly improved compared with the 4w IH group. The 6w IH + Ri group was improved compared with the 4w IH + Ri group. The results of immunohistochemistry showed that the expression of CB1R in IH group was significantly higher than that in NC group. The expression of CB1R in the IH + Ri group was lower than that in the IH group. With the prolongation of hypoxia, the expression of CB1R in bone cells of IH group increased. The expression level of CB1R in IH + Ri group decreased with the prolongation of intervention time. Correlation analysis showed that the expression rate of CB1R in bone cells was positively correlated with the level of TRAP in serum. Conclusion CIH increases serum TRAP levels and triggers metabolic bone disorder by activating bone CB1R. Intervention with CB1R antagonist (rimonabant) reduces the bone dysmetabolism in the CIH rat model.

Từ khóa


Tài liệu tham khảo

Passali D, Corallo G, Yaremchuk S, Longini M, Proietti F, Passali GC, Bellussi L (2015) Oxidative stress in patients with obstructive sleep apnoea syndrome. Acta Otorhinolaryngol Ital 35(6):420–425. https://doi.org/10.14639/0392-100x-895

Toraldo DM, Den F, Deb M, Scoditti E (2015) Obstructive sleep apnoea syndrome: a new paradigm by chronic nocturnal intermittent hypoxia and sleep disruption. Acta Otorhinolaryngol Ital 35(2):69–74

Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FA, Herzstein J, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP, Silverstein M, Tseng CW (2017) Screening for obstructive sleep apnea in adults: US preventive services task force recommendation statement. Jama 317(4):407–414. https://doi.org/10.1001/jama.2016.20325

Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG (2017) Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med 13(3):479–504. https://doi.org/10.5664/jcsm.6506

Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G, Vollenweider P, Tafti M, Haba-Rubio J (2015) Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 3(4):310–318. https://doi.org/10.1016/s2213-2600(15)00043-0

Subramani Y, Singh M, Wong J, Kushida CA, Malhotra A, Chung F (2017) Understanding phenotypes of obstructive sleep apnea: applications in anesthesia, surgery, and perioperative medicine. Anesth Analg 124(1):179–191. https://doi.org/10.1213/ane.0000000000001546

Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, Hamilton GS, Dharmage SC (2017) Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev 34:70–81. https://doi.org/10.1016/j.smrv.2016.07.002

Tufik S, Santos-Silva R, Taddei JA, Bittencourt LR (2010) Obstructive sleep apnea syndrome in the Sao Paulo epidemiologic sleep study. Sleep Med 11(5):441–446. https://doi.org/10.1016/j.sleep.2009.10.005

Reddy EV, Kadhiravan T, Mishra HK, Sreenivas V, Handa KK, Sinha S, Sharma SK (2009) Prevalence and risk factors of obstructive sleep apnea among middle-aged urban Indians: a community-based study. Sleep Med 10(8):913–918. https://doi.org/10.1016/j.sleep.2008.08.011

Deis S, Srivastava RK, Ruiz de Azua I, Bindila L, Baraghithy S, Lutz B, Bab I, Tam J (2018) Age-related regulation of bone formation by the sympathetic cannabinoid CB1 receptor. Bone 108:34–42. https://doi.org/10.1016/j.bone.2017.12.018

Terzi R, Yilmaz Z (2016) Bone mineral density and changes in bone metabolism in patients with obstructive sleep apnea syndrome. J Bone Miner Metab 34(4):475–481. https://doi.org/10.1007/s00774-015-0691-1

McPartland JM, Guy GW, Di Marzo V (2014) Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One 9(3):e89566. https://doi.org/10.1371/journal.pone.0089566

Sharma C, Sadek B, Goyal SN, Sinha S, Kamal MA, Ojha S (2015) Small molecules from nature targeting G-protein coupled cannabinoid receptors: potential leads for drug discovery and development. Evid Based Complement Alternat Med 2015:238482. https://doi.org/10.1155/2015/238482

Sophocleous A, Marino S, Kabir D, Ralston SH, Idris AI (2017) Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. Aging Cell 16(5):1051–1061. https://doi.org/10.1111/acel.12638

Whyte LS, Ford L, Ridge SA, Cameron GA, Rogers MJ, Ross RA (2012) Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol 165(8):2584–2597. https://doi.org/10.1111/j.1476-5381.2011.01519.x

Smith M, Wilson R, O'Brien S, Tufarelli C, Anderson SI, O'Sullivan SE (2015) The effects of the Endocannabinoids Anandamide and 2-Arachidonoylglycerol on human osteoblast proliferation and differentiation. PLoS One 10(9):e0136546. https://doi.org/10.1371/journal.pone.0136546

Halling Linder C, Ek-Rylander B, Krumpel M, Norgard M, Narisawa S, Millan JL, Andersson G, Magnusson P (2017) Bone alkaline phosphatase and tartrate-resistant acid phosphatase: potential co-regulators of bone mineralization. Calcif Tissue Int 101(1):92–101. https://doi.org/10.1007/s00223-017-0259-2

Bhaskara VK, Mohanam I, Gujrati M, Mohanam S (2014) Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells. PLoS One 9(8):e105555. https://doi.org/10.1371/journal.pone.0105555

Koren D, Dumin M, Gozal D (2016) Role of sleep quality in the metabolic syndrome. Diabetes Metab Syndr Obes 9:281–310. https://doi.org/10.2147/dmso.S95120

Gao X, Wu S, Dong Y, Huang Y, Chen Y, Qiao Y, Dou Z, Wang B (2018) Role of the endogenous cannabinoid receptor 1 in brain injury induced by chronic intermittent hypoxia in rats. Int J Neurosci 128(9):797–804. https://doi.org/10.1080/00207454.2017.1420069

Niu J, Sahni S, Liao S, Tucker KL, Dawson-Hughes B, Gao X (2015) Association between sleep duration, insomnia symptoms and bone mineral density in older Boston Puerto Rican adults. PLoS One 10(7):e0132342. https://doi.org/10.1371/journal.pone.0132342

Calik MW, Carley DW (2017) Effects of cannabinoid agonists and antagonists on sleep and breathing in Sprague-Dawley rats. Sleep 40(9). https://doi.org/10.1093/sleep/zsx112

Wang X, Yu Q, Yue H, Zhang J, Zeng S, Cui F (2016) Circulating Endocannabinoids and insulin resistance in patients with obstructive sleep apnea. Biomed Res Int 2016:9782031. https://doi.org/10.1155/2016/9782031

Dunn SL, Wilkinson JM, Crawford A, Bunning RAD, Le Maitre CL (2016) Expression of cannabinoid receptors in human osteoarthritic cartilage: implications for future therapies. Cannabis Cannabinoid Res 1(1):3–15. https://doi.org/10.1089/can.2015.0001

Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36(5):277–296. https://doi.org/10.1016/j.tips.2015.02.008

Thông tin
Thông tin xuất bản

Sleep and Breathing

Tập 24 Số 4

1441-1449

Thông tin tác giả